高级搜索
盖诺联合顺铂治疗中、晚期食管癌的临床疗效观察[J]. 肿瘤防治研究, 2006, 33(09): 682-685. DOI: 10.3971/j.issn.1000-8578.888
引用本文: 盖诺联合顺铂治疗中、晚期食管癌的临床疗效观察[J]. 肿瘤防治研究, 2006, 33(09): 682-685. DOI: 10.3971/j.issn.1000-8578.888
Clinical Study of Vinorelbine Combined with Cisplatin in the Treatment of Advanced Esophageal Cancer[J]. Cancer Research on Prevention and Treatment, 2006, 33(09): 682-685. DOI: 10.3971/j.issn.1000-8578.888
Citation: Clinical Study of Vinorelbine Combined with Cisplatin in the Treatment of Advanced Esophageal Cancer[J]. Cancer Research on Prevention and Treatment, 2006, 33(09): 682-685. DOI: 10.3971/j.issn.1000-8578.888

盖诺联合顺铂治疗中、晚期食管癌的临床疗效观察

Clinical Study of Vinorelbine Combined with Cisplatin in the Treatment of Advanced Esophageal Cancer

  • 摘要: 目的观察盖诺(NVB)联合顺铂(CDDP)的NP方案治疗食管癌的疗效和毒副反应。方法对46例食管癌患者应用NP方案进行治疗,其中NVB25~30mg/m2,静脉滴入,d1、d8给药;DDP30mg/m2,静脉冲入,d1~3给药,21~28天为1周期,每例至少治疗2个周期。结果46例患者中总有效率(RR)为45.7%(21/46),其中CR2.2%(1/46),PR43.5%(20/46),SD34.8%(16/46),PD19.6%(9/46),中位生存期9.6个月(2~24个月),主要毒副反应为骨髓抑制及消化道反应。结论盖诺联合顺铂治疗食管癌疗效确切,毒副反应可以耐受。

     

    Abstract: Objective To evaluate the efficiency and toxicity of combination chemotherapy with vinorelbine and cisplain in the treatment of advanced esophageal cancer. Methods Forty-six cases were treated with NP regimen, NVB 25-30mg/m 2,iv, d_ 1 and d_ 8; DDP 30mg/m 2,iv, from d_ 1 to d_ 3.The cycle was repeated every 21-28 days. Results The overall response rate was 45.7%(21/46), with CR 2.2%(1/46), PR 43.5%(20/46), SD 34.8%(16/46), and PD 19.6%(9/46). The median overall survival of the whole group was 9.6 months (2-...

     

/

返回文章
返回